Moreover, the scientific board of ECRI keeps exploring new concepts around interventional cardiology, heart failure, cardiac imaging, and pharmacotherapy. This institute has conducted ten trials so far in more than 20,000 cardiovascular patients globally.

Our research expertise is linked to the medical leadership at the Erasmus University Medical Center for Core Lab activities and trial design as well as to partnerships with leading investigators worldwide

Over the years, Cardialysis has set several milestones for itself and the cardiovascular domain. The BENESTENT study completed in 1994 revolutionized the use of coronary stents in catheterization laboratories. To date, this study remains one of the most cited papers in cardiovascular research. In 2010, the company reported the sponsor-driven RESOLUTE All Comers trial (2010, Medtronic) which is still used as a methodological reference for pivotal or post-marketing coronary stent trials. This study compared two drug-eluting stent platforms in an unrestricted coronary artery disease population using a non-inferiority trial design. Recently, Cardialysis has contributed to the sponsor-driven GALILEO trial (Bayer), randomizing the use of an anticoagulant versus an antiplatelet strategy after transcatheter aortic valve implantation in patients without other indication for anticoagulation. Contrary to the investigator’s hypothesis, GALILEO showed that anticoagulation was detrimental, highlighting the importance of randomized trials. These three studies were published in the New England Journal of Medicine.

Apart from its stellar performance in compliance-driven innovation, Cardialysis separates itself in the market with its organizational culture. “Our team comprises highly committed individuals who maintain dynamic interaction with the company’s partners across open communication channels,” says Dr. Spitzer. In 2020, the company undertook two fundamental changes in itself to operate as a leaner firm with a flat organizational hierarchy driven by an enhanced focus on data integrity, security, and transparency. During the COVID-19 pandemic, Cardialysis had ‘zero’ downtime and remained fully operational through the critical moments. Currently, the company is running 40 clinical investigations with different groups of services, including several full-service projects.

In 2021, Cardialysis aims to expand its team and forge a stronger and long-lasting relationship with industry players, including professional, independent, and knowledgeable cardiovascular research organizations.